(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-{(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy}-11-{(2S,3S,4R,6R)-4-hydroxy-6-methyl-3-morpholin-4-yl-tetrahydropyran-2-yloxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-{(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy}-11-{(2S,3S,4R,6R)-4-hydroxy-6-methyl-3-morpholin-4-yl-tetrahydropyran-2-yloxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
• 英文别名: CSY5602；(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3S,4R,6R)-4-hydroxy-6-methyl-3-morpholin-4-yloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
• 化学式: C₄₀H₇₄N₂O₁₃
• 分子量: 791.033
• InChiKey: ORFBUFOYMVNQTJ-WNSRQRFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  55
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  189
• 氢给体数：
  5
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-{(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy}-11-{(2S,3S,4R,6R)-4-hydroxy-6-methyl-3-morpholin-4-yl-tetrahydropyran-2-yloxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one 、 丙酸酐 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以72%的产率得到
  参考文献：
  名称：

  [EN] ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS
  [FR] COMPOSÉS ANTI-INFECTIEUX ET ANTIVIRAUX, ET COMPOSITIONS

  摘要：

  溶酶体积累的物质，能释放硝基氧基团、短链脂肪酸、厌氧代谢产物、硫醇或硫化物，常来自酯或类似不稳定键合，具有抗炎、抗癌和抗菌活性。它们在治疗感染性、炎症性和恶性疾病方面有用，能刺激免疫、促进锌吸收、抑制内体反应并增强蛋白酶抑制剂的抗病毒作用。这些化合物可用于治疗细菌性、病毒性和混合性肺炎。

  公开号：

  WO2021195126A1

文献信息

• Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
  申请人：Burnet Michael

  公开号：US20090093014A1

  公开（公告）日：2009-04-09

  This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

  这项发明涉及一种用于增强治疗剂效的化合物鉴定方法。该方法包括将化合物孵育在血细胞中；将免疫细胞与红细胞分离；并确定免疫细胞中化合物浓度与红细胞中化合物浓度之比；其中，该化合物包括一个运载体和一个治疗剂，其中运载体通过键合或连接物与治疗剂共价结合。
• US7579324B2
  申请人：——

  公开号：US7579324B2

  公开（公告）日：2009-08-25
• US7767797B1
  申请人：——

  公开号：US7767797B1

  公开（公告）日：2010-08-03
• US8357506B2
  申请人：——

  公开号：US8357506B2

  公开（公告）日：2013-01-22
• [EN] ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ANTI-INFECTIEUX ET ANTIVIRAUX, ET COMPOSITIONS
  申请人：BURNET MICHAEL W

  公开号：WO2021195126A1

  公开（公告）日：2021-09-30

  Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease and are immune stimulatory, promote zinc uptake, disable endosomal reactions and synergise anti-viral action of protease inhibitors. The compounds are useful for the treatment of bacterial, viral and mixed pneumonias.

  溶酶体积累的物质，能释放硝基氧基团、短链脂肪酸、厌氧代谢产物、硫醇或硫化物，常来自酯或类似不稳定键合，具有抗炎、抗癌和抗菌活性。它们在治疗感染性、炎症性和恶性疾病方面有用，能刺激免疫、促进锌吸收、抑制内体反应并增强蛋白酶抑制剂的抗病毒作用。这些化合物可用于治疗细菌性、病毒性和混合性肺炎。